Literature DB >> 29207339

Structure-activity relationships for inhibitors of Pseudomonas aeruginosa exoenzyme S ADP-ribosyltransferase activity.

Michael Saleeb1, Charlotta Sundin1, Öznur Aglar1, Ana Filipa Pinto2, Mahsa Ebrahimi2, Åke Forsberg3, Herwig Schüler2, Mikael Elofsson4.   

Abstract

During infection, the Gram-negative opportunistic pathogen Pseudomonas aeruginosa employs its type III secretion system to translocate the toxin exoenzyme S (ExoS) into the eukaryotic host cell cytoplasm. ExoS is an essential in vivo virulence factor that enables P. aeruginosa to avoid phagocytosis and eventually kill the host cell. ExoS elicits its pathogenicity mainly via ADP-ribosyltransferase (ADPRT) activity. We recently identified a new class of ExoS ADPRT inhibitors with in vitro IC50 of around 20 μM in an enzymatic assay using a recombinant ExoS ADPRT domain. Herein, we report structure-activity relationships of this compound class by comparing a total of 51 compounds based on a thieno [2,3-d]pyrimidin-4(3H)-one and 4-oxo-3,4-dihydroquinazoline scaffolds. Improved inhibitors with in vitro IC50 values of 6 μM were identified. Importantly, we demonstrated that the most potent inhibitors block ADPRT activity of native full-length ExoS secreted by viable P. aeruginosa with an IC50 value of 1.3 μM in an enzymatic assay. This compound class holds promise as starting point for development of novel antibacterial agents.
Copyright © 2017 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  2-Aminobenzamide; ADP-Ribosyltransferase; Bacterial exotoxins; ExoS; Pseudomonas aeruginosa; Quinazolines; Type III secretion

Mesh:

Substances:

Year:  2017        PMID: 29207339     DOI: 10.1016/j.ejmech.2017.11.036

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Pseudomonas aeruginosa Antivirulence Strategies: Targeting the Type III Secretion System.

Authors:  Joanna B Goldberg; Cristian V Crisan; Justin M Luu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 2.  Targeting ADP-ribosylation as an antimicrobial strategy.

Authors:  Giuliana Catara; Annunziata Corteggio; Carmen Valente; Giovanna Grimaldi; Luca Palazzo
Journal:  Biochem Pharmacol       Date:  2019-06-06       Impact factor: 5.858

3.  Synthesis and biological evaluation of dehydroabietic acid-pyrimidine hybrids as antitumor agents.

Authors:  Lin Huang; Rong Huang; Fuhua Pang; Anke Li; Guobao Huang; Xiaoqun Zhou; Qian Li; Fangyao Li; Xianli Ma
Journal:  RSC Adv       Date:  2020-05-11       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.